Pictet-Biotech HR AUD

Reference Data

ISIN LU2353392348
Valor Number 112071796
Bloomberg Global ID
Fund Name Pictet-Biotech HR AUD
Fund Provider Pictet Asset Management S.A. Genève, Switzerland
Phone: +41 58 323 10 24
www.assetmanagement.pictet
Fund Provider Pictet Asset Management S.A.
Representative in Switzerland Pictet Asset Management S.A.
Genève 73
Phone: +41 58 323 30 00
Distributor(s) Credit Suisse AG
Zürich
Phone: +41 44 333 11 11 UBS AG
Zürich
Phone: +41 44 234 11 11 Vontobel Fonds Services AG
Zürich
Phone: +41 58 283 74 77
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs.
Peculiarities

Fund Prices

Current Price * 727.24 AUD 23.12.2024
Previous Price * 726.37 AUD 20.12.2024
52 Week High * 853.66 AUD 16.07.2024
52 Week Low * 689.81 AUD 25.04.2024
NAV * 727.24 AUD 23.12.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 2,306,958,084
Unit/Share Assets *** 391,774
Trading Information SIX

Performance

YTD Performance -3.01% 29.12.2023
23.12.2024
YTD Performance (in CHF) -5.54% 29.12.2023
23.12.2024
1 month -8.00% 25.11.2024
23.12.2024
3 months -10.23% 23.09.2024
23.12.2024
6 months -5.23% 24.06.2024
23.12.2024
1 year -2.61% 27.12.2023
23.12.2024
2 years +5.19% 23.12.2022
23.12.2024
3 years -12.35% 23.12.2021
23.12.2024
5 years -19.40% 22.06.2021
23.12.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

argenx SE ADR 5.67%
Insmed Inc 4.52%
Sarepta Therapeutics Inc 4.05%
Intra-Cellular Therapies Inc 4.01%
TG Therapeutics Inc 3.30%
Vaxcyte Inc Ordinary Shares 3.24%
Blueprint Medicines Corp 3.10%
Gilead Sciences Inc 3.01%
SpringWorks Therapeutics Inc Ordinary Shares 2.81%
Cytokinetics Inc 2.80%
Last data update 30.11.2024

Cost / Risk

TER *** 2.765%
TER date *** 31.05.2024
Performance Fee ***
PTR
Max. Management Fee *** 2.90%
Ongoing Charges *** 2.75%
SRRI ***
SRRI date *** 31.07.2021

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 *** Sustainable Investment
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)